{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:08:28Z","timestamp":1790957308939,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2019R1A2C2010408"],"award-info":[{"award-number":["NRF-2019R1A2C2010408"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jconrel.2022.09.040","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T20:54:58Z","timestamp":1665089698000},"page":"713-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy"],"prefix":"10.1016","volume":"351","author":[{"given":"Jong Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmeyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoosoo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Yeol","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ick Chan","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.09.040_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008362","article-title":"RNAi therapies: drugging the Undruggable","volume":"6","author":"Wu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(04)00293-4","article-title":"Dicers at RISC: the mechanism of RNAi","volume":"117","author":"Tijsterman","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.11.019","article-title":"Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance","volume":"198","author":"Yhee","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0025","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1002\/anie.201814289","article-title":"The siRNAsome: a cation-free and versatile nanostructure for siRNA and drug co-delivery","volume":"58","author":"Zheng","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0030","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/smll.201402377","article-title":"Overcoming multiple drug resistance by spatial\u2013temporal synchronization of epirubicin and pooled siRNAs","volume":"11","author":"Chen","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbrc.2017.05.103","article-title":"Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles","volume":"489","author":"Kim","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0040","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.7150\/thno.32416","article-title":"Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/10717544.2016.1267821","article-title":"A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo","volume":"24","author":"He","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nantod.2012.06.013","article-title":"Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance","volume":"7","author":"Creixell","year":"2012","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0055","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/smll.201303951","article-title":"Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy","volume":"10","author":"Chen","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jconrel.2015.08.032","article-title":"Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo","volume":"220","author":"Lee","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep06878","article-title":"Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA","volume":"4","author":"Yoon","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0070","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2014.09.001","article-title":"Nanocarrier mediated delivery of siRNA\/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances","volume":"194","author":"Gandhi","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0075","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1002\/anie.201601273","article-title":"Ultra-pH-responsive and tumor-penetrating nanoplatform for targeted siRNA delivery with robust anti-cancer efficacy","volume":"55","author":"Xu","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0080","doi-asserted-by":"crossref","first-page":"2009768","DOI":"10.1002\/adfm.202009768","article-title":"Photocrosslinked bioreducible polymeric nanoparticles for enhanced systemic siRNA delivery as cancer therapy","volume":"31","author":"Karlsson","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","article-title":"Recent progress in development of siRNA delivery vehicles for cancer therapy","volume":"104","author":"Kim","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0090","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.7150\/thno.37198","article-title":"Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41551-018-0240-z","article-title":"Efficient siRNA delivery with non-cationic carriers","volume":"2","author":"Choi","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0100","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1021\/acs.bioconjchem.8b00321","article-title":"Functionalization of halloysite nanotubes via grafting of dendrimer for efficient intracellular delivery of siRNA","volume":"29","author":"Long","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0105","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.7150\/thno.33921","article-title":"Advances in intracellular delivery through supramolecular self-assembly of oligonucleotides and peptides","volume":"9","author":"Kim","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0110","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jconrel.2021.03.004","article-title":"Cytocompatibility, membrane disruption, and siRNA delivery using environmentally responsive cationic nanogels","volume":"332","author":"Spencer","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2019.06.022","article-title":"Chemical modulation of siRNA lipophilicity for efficient delivery","volume":"307","author":"Tai","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0120","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: from research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0125","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/molecules24122211","article-title":"Current aspects of siRNA bioconjugate for in vitro and in vivo delivery","volume":"24","author":"Tai","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0130","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"Rna"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0092-8674(03)00759-1","article-title":"Asymmetry in the assembly of the RNAi enzyme complex","volume":"115","author":"Schwarz","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.526455","article-title":"siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects","volume":"11","author":"Neumeier","year":"2021","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0145","first-page":"101","article-title":"Therapeutic siRNA: state of the art, signal transduction and targeted","volume":"5","author":"Hu","year":"2020","journal-title":"Therapy"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0150","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0165","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality","volume":"33","author":"Elmen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0170","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.1093\/nar\/gkx558","article-title":"Amide linkages mimic phosphates in RNA interactions with proteins and are well tolerated in the guide strand of short interfering RNAs","volume":"45","author":"Mutisya","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0175","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/anie.201007012","article-title":"Amides as excellent mimics of phosphate linkages in RNA","volume":"50","author":"Selvam","year":"2011","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/mt.2011.294","article-title":"Action and reaction: the biological response to siRNA and its delivery vehicles","volume":"20","author":"Kanasty","year":"2012","journal-title":"Mol. Therapy."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0185","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1039\/b918869j","article-title":"Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo","volume":"6","author":"Laursen","year":"2010","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2022.09.040_bb0195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17512433.2022.2075848","article-title":"Givosiran for the treatment of acute hepatic porphyria","volume":"15","author":"Ventura","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/nat.2018.0725","article-title":"Improving siRNA DeliveryIn vivo through lipid conjugation","volume":"28","author":"Osborn","year":"2018","journal-title":"Nucleic Acid Therap."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0205","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jconrel.2020.02.032","article-title":"Small interfering RNA from the lab discovery to patients\u2019 recovery","volume":"321","author":"Caillaud","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0215","doi-asserted-by":"crossref","first-page":"E6490","DOI":"10.1073\/pnas.1621240114","article-title":"Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing","volume":"114","author":"Sarett","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/nat.2017.0690","article-title":"Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay","volume":"27","author":"Godinho","year":"2017","journal-title":"Nucleic Acid Therap."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0230","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17425247.2018.1473375","article-title":"Recent preclinical and clinical advances in oligonucleotide conjugates","volume":"15","author":"Craig","year":"2018","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24122211","article-title":"Current aspects of siRNA bioconjugate for in vitro and in vivo delivery","volume":"24","author":"Tai","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0240","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/nar\/gky1232","article-title":"Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways","volume":"47","author":"Osborn","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0245","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0250","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0255","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/nar\/gkr1002","article-title":"Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group","volume":"40","author":"Petrova","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.omtn.2016.12.011","article-title":"Cholesterol-containing nuclease-resistant siRNA accumulates in tumors in a carrier-free mode and silences MDR1 gene","volume":"6","author":"Chernikov","year":"2017","journal-title":"Mol. Therapy - Nucleic Acids"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0265","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0270","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1535-7163.MCT-17-1144","article-title":"Efficient gene silencing in brain tumors with hydrophobically modified siRNAs","volume":"17","author":"Osborn","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: from research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0280","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood\u2013brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0285","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.38","article-title":"Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol. Therapy - Nucleic Acids"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0290","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/nar\/gky1232","article-title":"Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways","volume":"47","author":"Osborn","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0295","first-page":"1","article-title":"Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0300","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/smll.201001589","article-title":"Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles","volume":"7","author":"Yang","year":"2011","journal-title":"small"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-0716-1298-9_18","article-title":"Cell-penetrating peptides delivering siRNAs: an overview","volume":"2282","author":"Falato","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0310","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.08.004","article-title":"Functional peptides for siRNA delivery","volume":"110-111","author":"Tai","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0315","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2019.07.010","article-title":"Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment","volume":"214","author":"Cummings","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0320","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.chembiol.2004.06.006","article-title":"Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells","volume":"11","author":"Chiu","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0325","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/bc070077d","article-title":"Lung delivery studies using siRNA conjugated to TAT(48\u221260) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity","volume":"18","author":"Moschos","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0330","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1096\/fj.06-6502com","article-title":"Delivery of short interfering RNA using endosomolytic cell-penetrating peptides","volume":"21","author":"Lundberg","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0335","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.7150\/thno.19863","article-title":"High-yield synthesis of monomeric LMWP(CPP)-siRNA covalent conjugate for effective cytosolic delivery of siRNA","volume":"7","author":"Ye","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0340","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.apsb.2017.11.011","article-title":"Improved method for synthesis of low molecular weight protamine-siRNA conjugate","volume":"8","author":"Yu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0345","doi-asserted-by":"crossref","first-page":"29159","DOI":"10.1038\/srep29159","article-title":"Topical and targeted delivery of siRNAs to melanoma cells using a fusion peptide carrier","volume":"6","author":"Ruan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0350","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13273-019-0028-6","article-title":"Covalent conjugates of granulin-epithelial precursor-siRNA with arginine-rich peptide for improved stability and intracellular delivery in hepatoma cells","volume":"15","author":"Choi","year":"2019","journal-title":"Mol. Cell. Toxicol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0355","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1038\/s41598-019-42456-8","article-title":"Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines","volume":"9","author":"Patel","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0360","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/bc200235q","article-title":"Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA","volume":"22","author":"Alam","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0365","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.omtn.2021.03.013","article-title":"Advancing peptide siRNA-carrier designs through L\/D-amino acid stereochemical modifications to enhance gene silencing","volume":"24","author":"Holjencin","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0370","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.omtn.2021.08.004","article-title":"Feasibility of cRGD conjugation at 5\u2032-antisense strand of siRNA by phosphodiester linkage extension","volume":"25","author":"Zhou","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0375","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1021\/acsomega.8b00850","article-title":"Enhanced intercellular delivery of cRGD-siRNA conjugates by an additional Oligospermine modification","volume":"3","author":"Nakamoto","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0380","doi-asserted-by":"crossref","first-page":"11805","DOI":"10.1093\/nar\/gku831","article-title":"Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA","volume":"42","author":"Liu","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0385","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/10717544.2016.1267821","article-title":"A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo","volume":"24","author":"He","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0390","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/bc300050j","article-title":"Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides","volume":"23","author":"Sioud","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/0886022X.2018.1450761","article-title":"Protective effect of Gelofusine against cRGD-siRNA-induced nephrotoxicity in mice","volume":"40","author":"Liao","year":"2018","journal-title":"Ren. Fail."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0400","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000479980","article-title":"Modulating cytotoxic effector functions by fc engineering to improve cancer therapy","volume":"44","author":"Kellner","year":"2017","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0405","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/08820139.2017.1301466","article-title":"Variable heavy chain domain derived from a cell-penetrating anti-DNA monoclonal antibody for the intracellular delivery of biomolecules","volume":"46","author":"Im","year":"2017","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0410","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120940","article-title":"Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA","volume":"606","author":"Yu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0420","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/acs.molpharmaceut.0c01001","article-title":"Nanobody\u2013siRNA conjugates for targeted delivery of siRNA to cancer cells","volume":"18","author":"Zavoiura","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120940","article-title":"Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA","volume":"606","author":"Yu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0430","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody fc engineering for enhanced neonatal fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0435","article-title":"Antibody\u2013siRNA conjugates (ARC): emerging siRNA drug formulation","volume":"15","author":"Cao","year":"2022","journal-title":"Med. Drug Disc."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040838","article-title":"Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates","volume":"10","author":"Dugal-Tessier","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0445","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function","volume":"4","author":"Liu","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0450","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1021\/ac100575n","article-title":"Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC\u2212MS analysis","volume":"82","author":"Liu","year":"2010","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0455","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/antib4030197","article-title":"Antibody conjugates: from heterogeneous populations to defined reagents","volume":"4","author":"Dennler","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17020194","article-title":"Methods to design and synthesize antibody-drug conjugates (ADCs)","volume":"17","author":"Yao","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0465","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 gene silencing by aptamer-siRNA chimera as selective therapeutic for glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0470","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1172\/JCI73174","article-title":"CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells","volume":"124","author":"Herrmann","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0475","article-title":"Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0480","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5030051","article-title":"Toward the selection of cell targeting aptamers with extended biological functionalities to facilitate endosomal escape of cargoes","volume":"5","author":"Tawiah","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0490","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0495","first-page":"563","article-title":"Engineering a targeted delivery platform using Centyrins","volume":"29","author":"Goldberg","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0500","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.ymthe.2021.02.015","article-title":"Centyrin ligands for extrahepatic delivery of siRNA","volume":"29","author":"Klein","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119337","article-title":"Advances in siRNA delivery strategies for the treatment of MDR cancer","volume":"274","author":"Subhan","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0515","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0520","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ymthe.2019.06.009","article-title":"Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular cancer models","volume":"27","author":"Kim","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0525","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1021\/bc100346n","article-title":"Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation","volume":"21","author":"Zhu","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0530","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/bc4001257","article-title":"Reducible hyaluronic acid-siRNA conjugate for target specific gene silencing","volume":"24","author":"Park","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0535","doi-asserted-by":"crossref","unstructured":"Y. Wen, H. Bai, J. Zhu, X. Song, G. Tang, J. Li, A supramolecular platform for controlling and optimizing molecular architectures of siRNA targeted delivery vehicles, Sci. Adv., 6 eabc2148.","DOI":"10.1126\/sciadv.abc2148"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0540","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejps.2017.11.024","article-title":"Cyclodextrin-siRNA conjugates as versatile gene silencing agents","volume":"114","author":"Malhotra","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0545","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1021\/acs.bioconjchem.9b00204","article-title":"Dextran-conjugated caged siRNA nanoparticles for photochemical regulation of RNAi-induced gene silencing in cells and mice","volume":"30","author":"Chen","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0550","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/acs.bioconjchem.6b00322","article-title":"Artificial control of gene silencing activity based on siRNA conjugation with polymeric molecule having coil-globule transition behavior","volume":"27","author":"Che Harun","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0560","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nbt0918-777","article-title":"Alnylam launches era of RNAi drugs","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0565","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120940","article-title":"Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA","volume":"606","author":"Yu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0575","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/acs.bioconjchem.6b00322","article-title":"Artificial control of gene silencing activity based on siRNA conjugation with polymeric molecule having coil\u2013globule transition behavior","volume":"27","author":"Che Harun","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0580","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","article-title":"Chemical modification of siRNAs to improve serum stability without loss of efficacy","volume":"342","author":"Choung","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0585","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1093\/nar\/gkv298","article-title":"2\u2019-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF","volume":"43","author":"Shen","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0590","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: from research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0595","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/nat.2016.0639","article-title":"Impact of oligonucleotide structure, chemistry, and delivery method on in vitro cytotoxicity","volume":"27","author":"Janas","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0600","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality","volume":"33","author":"Elmen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0605","doi-asserted-by":"crossref","first-page":"30377","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0610","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0615","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0620","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1021\/bi0343774","article-title":"RNA interference in mammalian cells by chemically-modified RNA","volume":"42","author":"Braasch","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0625","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1093\/nar\/gkh936","article-title":"RNA interference using boranophosphate siRNAs: structure-activity relationships","volume":"32","author":"Hall","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0630","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/nar\/gkl339","article-title":"High potency silencing by single-stranded boranophosphate siRNA","volume":"34","author":"Hall","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0635","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/nass\/nrn331","article-title":"Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators","author":"Shaw","year":"2008","journal-title":"Nucleic Acids Symp Ser (Oxf)"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0640","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1093\/nar\/gku235","article-title":"Amides are excellent mimics of phosphate internucleoside linkages and are well tolerated in short interfering RNAs","volume":"42","author":"Mutisya","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0645","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1039\/C3OB42532K","article-title":"Synthesis, biophysical studies and RNA interference activity of RNA having three consecutive amide linkages","volume":"12","author":"Tanui","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0650","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0655","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cbic.201600130","article-title":"5\u2032-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates","volume":"17","author":"Parmar","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2022.09.040_bb0660","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1021\/jo2012225","article-title":"Chemical modification of siRNA bases to probe and enhance RNA interference","volume":"76","author":"Peacock","year":"2011","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0665","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","article-title":"Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers","volume":"5","author":"Amantana","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0670","doi-asserted-by":"crossref","first-page":"16240","DOI":"10.1021\/jacs.0c04335","article-title":"Synthesis and characterization of Thiophosphoramidate Morpholino oligonucleotides and chimeras","volume":"142","author":"Langner","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0675","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/156802607780487740","article-title":"Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity","volume":"7","author":"Summerton","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0680","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cbdd.13815","article-title":"Evolution of peptide nucleic acid with modifications of its backbone and application in biotechnology","volume":"97","author":"Das","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jconrel.2022.09.040_bb0685","doi-asserted-by":"crossref","first-page":"551","DOI":"10.15171\/apb.2018.064","article-title":"Potential of peptide nucleic acids in future therapeutic applications","volume":"8","author":"Montazersaheb","year":"2018","journal-title":"Adv. Pharm. Bull."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922006356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922006356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:38:33Z","timestamp":1759163913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922006356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":137,"alternative-id":["S0168365922006356"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.040","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}